OncoMatch/Clinical Trials/NCT05826535
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Is NCT05826535 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Rondecabtagene autoleucel (ronde-cel) and Fludarabine for relapsed non-hodgkin lymphoma.
Treatment: Rondecabtagene autoleucel (ronde-cel) · Fludarabine · Cyclophosphamide — This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic anti-cancer therapy
Cannot have received: genetically modified cell therapy
Cannot have received: car-t cell therapy targeting cd19 with fmc63-based car (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel)
Cannot have received: allogeneic stem cell transplantation
Lab requirements
Blood counts
anc ≥ 1000/µl; platelet count ≥ 50,000/µl; absolute lymphocyte count (alc) ≥ 200/µl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California-Irvine Medical Center · Irvine, California
- Cedars-Sinai Medical Center · Los Angeles, California
- University of California, Los Angeles (UCLA) Medical Center · Los Angeles, California
- Scripps Clinic · San Diego, California
- Colorado Blood Cancer Institute · Denver, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05826535 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior genetically modified cell therapy, car-t cell therapy targeting cd19 with fmc63-based car, allogeneic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify